fda shortage tirzepatide Compounding pharmacies can resume making as reconsiders FDA backtracks over Eli Lilly

JANUMET is not recommended in patients with an eGFR between 30 and less than 45 mL/min/1.73 m2 because these patients require a lower dosage of sitagliptin than what is available in the fixed combination JANUMET product

About the reviewerView full bio Dr Doug McKechnie, MRCGP Medical Writer MA, MBBS, MSc, DRCOG, MRCP(UK), MRCGP(2021), FHEA Dr Doug McKechnie is an NHS GP working in London

The lightweight, non-greasy formula, easily absorbed into the scalp through phosolipids/liposomal formula for up to 7x better absorption

[DOI] [PMC free article] [PubMed] [Google Scholar] 50.Zhou ZD, et al

While clinical trials show it is not a replacement for stimulants in hyperactive ADHD, it demonstrates a unique ability to upregulate dopamine receptors and specifically improve symptoms in inattentive ADHD